Notice Number: NOT-CA-19-035
Release Date: March 15, 2019
Response Date: May 07, 2019
National Cancer Institute (NCI)
The National Cancer Institute (NCI) is seeking broad input fromentities and persons with expertise, experience, and interest in the development of peptide-based cancer therapeutics and vaccines. This input is needed so that the NCI can more effectively deploy technologies and acquisition strategies to accelerate the development, availability, and pre-clinical evaluation of peptide-based cancer therapeutics and vaccines and to advance novel approaches for warranted clinical testing of such agents in humans.
In recent years, several early-phase clinical studies have demonstrated proof-of-concept, safety, and feasibility for the application of individualized cancer vaccines and therapeutics based on genomic identification of cancer neoepitopes and then modifying immune responses to these epitopes. Modification of the immune response can be mediated by vaccination with the use of manufactured peptide neoantigens for immune presentation via either Class I or Class II MHC. Alternatively, manufactured peptides may be functionalized to facilitate an intended immune response or biological outcome that promotes cancer regression. The NCI is considering the procurement of clinical grade peptides in small batches and the advancement of innovative technologies for the rapid production and novel use of peptides to support intramural and extramural research involving personalized, neoantigen-specific peptide vaccine strategies.
All stakeholders with an interest in developing strategies for cancer treatment and vaccination through the application of peptide-based approaches are invited to provide information. Every response should mention every respondent's membership or affiliation within industry, government, or academia.
NCI is seeking information that includes, but is not limited to, perspectives on the following areas:
How to Submit a Response
All responses must be submitted via email to Dr. Jason Yovandich at firstname.lastname@example.org by May 7, 2019. Please include the Notice number (NOT-CA-19-035) in the subject line. Response to this RFI Notice is voluntary. Responders are free to address any or all of the categories listed above. Do not include any proprietary, classified, confidential, and/or sensitive information in your response.
Confidentiality and Use at the NCI
All individual responses will be treated as and kept confidential. Any identifiers (e.g., names, institutions, e-mail addresses, etc.) will be removed when responses are compiled. Only the processed, anonymized results will be shared internally with NCI staff members, as appropriate. The NCI will use the information submitted in response to this RFI Notice at its discretion and will not provide comments to any responder's submission. The collected information will be reviewed by NCI staff, may appear in reports, and may be shared publicly on an NCI website.
The Government reserves the right to use any non-proprietary technical information in summaries of the state of the science, and any resultant solicitation(s). The NCI may use the information gathered by this RFI to inform the development of future funding opportunity announcements.
This RFI Notice is for information and planning purposes only and should not be construed as a solicitation or as an obligation on the part of the Federal Government, the Department of Health and Human Services (HHS), the National Institutes of Health (NIH), or the National Cancer Institute (NCI). No basis for claims against the U.S. Government shall arise as a result of a response to this RFI Notice or from the Government’s use of such information.
Please direct all inquiries to:
Jason Yovandich, Ph.D., RAC
National Cancer Institute (NCI)